Chair: Peter Rossing (DNK)
| 18:45 – 18:50 | Welcome and introductions | Peter Rossing (DNK) |
| 18:50 – 19:00 | The importance of guidelines for identification and treatment of CKD in T2D: Where are we now | Janet McGill (USA) |
| 19:00 – 19:20 | The cardiorenal benefits of nonsteroidal MRAs: Insights from across the CKD in T2D patient spectrum | Peter Rossing (DNK) |
| 19:20 – 19:35 | Finerenone in clinical practice: Approaches for optimising the patient experience | Magnus Löndahl (SWE) |
| 19:35 – 19:45 | Q&A and close | Peter Rossing (DNK) |
- 21.09.2022
- 18:45 - 19:45
- Hellerström Hall
